Uncategorized – Page 15570 – 1stOncology™: Cancer Intelligence Service

Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

On March 5, 2018 Endocyte, Inc. (NASDAQ:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment , reported that the company’s management team will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12th at 2:50 p.m. EDT (Press release, Eleven Biotherapeutics, MAR 5, 2018, http://ir.elevenbio.com/news-releases/news-release-details/eleven-biotherapeutics-present-cowen-and-company-38th-annual [SID1234524389]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

A live audio webcast of the Company’s presentation can be accessed by visiting "Events & Presentations" under the Investors & News section of Endocyte’s website at www.endocyte.com. The webcast will be archived shortly after the live event, and a replay will be available on the Company’s website for 90 days following the conference.

Apollo Endosurgery, Inc. to Participate at the 30th Annual ROTH Conference

On March 5, 2018 Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, reported that Company management is scheduled to present at the 30th Annual ROTH Conference being held March 11-14, 2018 at the Ritz-Carlton Laguna Niguel in Orange County, CA. The presentation is scheduled for Monday, March 12, 2018 at 11:00 am PT (Press release, , MAY 5, 2018, https://www.thestreet.com/newsletters [SID1234524626]).

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Ophthotech has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Ophthotech, 2018, MAR 5, 2018, View Source [SID1234524363]).

20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Kitov Pharmaceuticals has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 20-F, Kitov Pharmaceuticals , 2018, MAR 5, 2018, View Source [SID1234524587]).

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

AnaptysBio has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, AnaptysBio, 2018, MAR 5, 2018, View Source [SID1234527558]).

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!

Category: Uncategorized

Eleven Biotherapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

Apollo Endosurgery, Inc. to Participate at the 30th Annual ROTH Conference

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]